2013•Pediatric RheumatologyOpen access

P01-031 – Anakinra for colchicine resistant FMF

Ilan Ben‐Zvi, OL Kukuy, Merav Lidar, Olga Feld, Oleg Perski, Shaye Kivity, Pnina Langevitz, B Pistrom, Avi Livneh

Abstract

About 10-20% of Familial Mediterranean Fever (FMF) patients do not achieve complete remission, due to colchicine resistance or sensitivity. Disease control in these patients is still an unmet challenge. Case reports and a small case control study, suggest a role for interleukin 1 beta blockage, particularly anakinra, in the management of this limitation of colchicines.

Open-access reader

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Anakinra, Familial Mediterranean fever, Colchicine, Medicine, Rheumatology, Internal medicine, Disease, Gastroenterology